Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Andreas Ejlegard: The Promise of Smarter Antithrombotic Therapy with Cereno Scientific
Andreas Ejlegård; Michael Holinstat/ LinkedIn
May 24, 2026, 00:54

Andreas Ejlegard: The Promise of Smarter Antithrombotic Therapy with Cereno Scientific

Andreas Ejlegard, Sales Development Manager at Rexel Sverige, shared a post on LinkedIn about recent article by Livia Stanger et al., published in Blood Journal, adding:

“In thrombosis, the tradeoff has almost always been the same.

Reduce clotting

  • increase bleeding risk

That balance defines much of cardiovascular medicine today.

Which is why programs aiming to break that paradigm are so interesting.

A great update highlighting how Cereno Scientific is expanding CS585 into antiphospholipid syndrome, APS.

APS is a rare autoimmune thrombotic disease where abnormal clot formation can lead to severe long term complications.

And this is where CS585 stands out conceptually.

Not just another anticoagulant.

But a selective oral IP receptor agonist designed to:

  • inhibit platelet activation
  • prevent thrombosis
  • preserve normal coagulation function
  • potentially avoid increased bleeding risk

That last part is the holy grail in thrombosis.

Because current antithrombotic therapies are often limited precisely by bleeding complications.

What also deserves attention is the scientific foundation behind the program.

CS585 originated from research at the University of Michigan and continues to advance through collaboration with Michael Holinstat and his team.

Strong credit to Michael Holinstat and the translational work behind the platform.

The preclinical data have already shown something highly unusual:

prevention of thrombosis without increased risk of bleeding (The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor, 10.1182/blood.2023020622)

If replicated clinically, that is not incremental improvement.

That is category redefining.

Especially in diseases requiring long term thrombosis prevention, where physicians constantly balance efficacy against safety.

So the expansion into APS feels strategically logical.

Not just broadening indication scope.

But stress testing the biology in one of the most clinically challenging thrombotic settings.

Not just thinner blood.

But smarter thrombosis control.”

Title: The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor

Authors: Livia Stanger, Adriana Yamaguchi, Pooja Yalavarthi, Sylviane Lambert, Devin Gilmore, Andrew Rickenberg, Catherine Luke, Kiran Kumar, Andrea T Obi, Andrew White, Niklas Bergh, Björn Dahlöf, Michael Holinstat

Andreas Ejlegard

Stay updated on all scientific advances with Hemostasis Today.

Adriana Yamaguchi Andrea T Obi Andreas Ejlegård Andrew Rickenberg Andrew White Björn Dahlöf Catherine Luke Devin Gilmore Health Hematology Hemostasis Hemostasis News Hemostasis Today Kiran Kumar Livia Stanger Medicine Michael Holinstat Niklas Bergh Pooja Yalavarthi Sylviane Lambert
NewsFeed